Physician profile
Brian Shih
NPI 1063483162
$14,803.98
in general payments reported to CMS, 2019-2025
29 companies · $1,668 in 2025
The $1,668 reported for 2025 was more than what 78% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,499 · 2020: $1,186 · 2021: $1,636 · 2022: $4,318 · 2023: $2,057 · 2024: $2,441 · 2025: $1,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,493 · Travel and Lodging: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,493.23 |
| Travel and Lodging | $671.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $3,590.42 | 2019-2024 | Senza |
| Ibsa Pharma INC. | $1,618.23 | 2021-2025 | Tirosint, Licart, Tirosint |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,617.43 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $1,554.82 | 2019-2025 | Belbuca, Xtampza |
| Saluda Medical Americas, INC. | $1,464.87 | 2022-2025 | Evoke, Evoke Scs |
| Abbott Laboratories | $784.98 | 2019-2024 | Proclaim, Eterna |
| Boston Scientific Corporation | $703.61 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Si-Bone, INC. | $545.29 | 2022-2023 | |
| Scilex Pharmaceuticals INC. | $520.52 | 2019-2023 | Ztlido |
| Pfizer INC. | $296.11 | 2019-2020 | |
| Globus Medical, INC. | $281.64 | 2025 | Senza |
| Redhill Biopharma INC. | $271.76 | 2020-2023 | Movantik, Talicia, Aemcolo |
| Daiichi Sankyo INC. | $266.79 | 2019 | |
| Horizon Therapeutics Plc | $248.57 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $236.92 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $124.77 | 2019-2021 | |
| Stryker Corporation | $118.54 | 2025 | Mild Device Kit |
| Valinor Pharma, LLC | $84.79 | 2023-2024 | Movantik |
| Abbvie INC. | $67.41 | 2023-2024 | Qulipta, Ubrelvy |
| Biotronik Nro, INC. | $59.96 | 2023-2024 | Prospera, Biotronik |
| Arbor Pharmaceuticals, INC. | $58.63 | 2020-2021 | |
| Baxter Healthcare | $58.38 | 2024 | Preveleak |
| Astrazeneca Pharmaceuticals LP | $43.57 | 2019-2020 | |
| Virtus Pharmaceuticals LLC | $36.25 | 2021-2024 | Levorphanol Tartrate |
| Kowa Pharmaceuticals America, INC. | $35.44 | 2022 | |
| Idorsia Pharmaceuticals US INC | $33.53 | 2023 | Quviviq |
| Forte Bio-Pharma LLC | $33.37 | 2023 | Prolate, Nalocet |
| Grt US Holding, INC. | $28.76 | 2021 | |
| Kaleo, INC. | $18.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Shih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.